Use of safinamide for treatment of Parkinson disease: real-world data from Spain
Safinamide is a monoamine oxidase B inhibitor that was approved in Europe in February 2015 to complement a stable dose of levodopa in monotherapy or in combination with other antiparkinsonian agents in adults affected by mid-stage or advanced Parkinson disease (PD) with fluctuations. It is character...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2025-07-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/use-of-safinamide-for-treatment-of-parkinson-disease-real-world-data-from-spain/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|